1. Home
  2. UFCS vs DRUG Comparison

UFCS vs DRUG Comparison

Compare UFCS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

HOLD

Current Price

$34.38

Market Cap

933.8M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$87.21

Market Cap

856.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UFCS
DRUG
Founded
1946
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
933.8M
856.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UFCS
DRUG
Price
$34.38
$87.21
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$37.50
$106.75
AVG Volume (30 Days)
94.8K
274.2K
Earning Date
02-10-2026
02-13-2026
Dividend Yield
1.86%
N/A
EPS Growth
118.04
N/A
EPS
4.24
N/A
Revenue
$1,353,781,000.00
N/A
Revenue This Year
$10.11
N/A
Revenue Next Year
$3.33
N/A
P/E Ratio
$8.11
N/A
Revenue Growth
12.12
N/A
52 Week Low
$24.11
$23.18
52 Week High
$37.91
$123.75

Technical Indicators

Market Signals
Indicator
UFCS
DRUG
Relative Strength Index (RSI) 37.93 52.90
Support Level $34.85 $81.72
Resistance Level $35.69 $91.00
Average True Range (ATR) 0.91 8.52
MACD -0.16 -0.71
Stochastic Oscillator 2.96 28.82

Price Performance

Historical Comparison
UFCS
DRUG

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: